Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070042 · ClinicalTrials.gov registry record · NA
Oxybutynin and Omega-3 for OAB (Overactive Bladder)
A NA study, sponsored by TriHealth.
- Terminated
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02070042: Clinical Trial NA study, sponsored by TriHealth.
NCT02070042 is a NA study that was terminated before completion, run by TriHealth. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02070042, a NA study, was terminated before completion, sponsored by TriHealth.
- TERMINATED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard first-line treatment for overactive bladder syndrome, will improve symptoms and quality of life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse effects of oxybutynin. Hypothesis * Primary: Omega-3 will enhance the beneficial role of oxybutynin in the treatment of overactive bladder (OAB) * Secondary: Omega-3 will reduce the side effects of dry eyes and constipation associated with oxybutynin
Primary Outcome
The number of times the subjects urinates per day will be decreased
Interventions
- DRUG Placebo
- DRUG Omega 3 Fatty Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-09 |
| Phase | NA |
Why NCT02070042 stopped before completion
NCT02070042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02070042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02070042 about?
NCT02070042 is a clinical study titled "Oxybutynin and Omega-3 for OAB (Overactive Bladder)". We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard first-line treatment for overactive bladder syndrome, will improve symptoms and quality of life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse effects of oxybutynin. Hypothes...
What is the current status of trial NCT02070042?
This trial is currently terminated. It is a NA study. The enrollment target is 31 participants. The study started on 2014-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02070042?
The interventions under investigation include: Placebo (DRUG), Omega 3 Fatty Acid (DRUG).
Who is sponsoring clinical trial NCT02070042?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02070042's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia